DPM

Quick links to important sections

DPM

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of DPM

Quick Facts

Property Description
Active ingredient Dexchlorpheniramine maleate
Form Tablets, Syrup, Oral solution
Pharmacological class First-generation antihistamine
General Purpose Relief of symptoms associated with allergic conditions
Origin Synthetic stereoisomer

What Type of Medicine is DPM?

DPM is a synthetic drug classified as a first-generation antihistamine that belongs to the broader pharmacological class of H1-receptor antagonists. Its primary function is clinically recognized for addressing the discomfort and symptoms associated with allergic conditions and hypersensitivity reactions.

The active pharmaceutical substance in DPM is Dexchlorpheniramine maleate, a precise chemical entity derived from the older, racemic compound known as chlorpheniramine. Dexchlorpheniramine is defined chemically as the S-enantiomer, or active stereoisomer, of chlorpheniramine, a structure that pharmacological studies have confirmed makes it significantly more potent than the older mixture. The drug's classification as a first-generation agent is a defining characteristic, differentiating it from newer classes, because these compounds readily cross the blood-brain barrier. This unique feature contributes to its characteristic sedative properties—a differentiating factor sought in specific treatment scenarios.


Composition, Forms, and General Purpose

The active ingredient, Dexchlorpheniramine maleate, exerts its general therapeutic effect through histamine H1-receptor blockade, which is the fundamental process by which it interrupts the body’s allergic response.

This mechanism means that the substance occupies the specific cellular binding sites, known as H1-receptors, that histamine normally attaches to when released during an allergic reaction. By preventing this attachment, Dexchlorpheniramine achieves its general purpose: to inhibit the cascade of physical symptoms—such as itching, sneezing, and runny nose—that arise from the uninhibited action of histamine. The medication is administered via the oral route and is typically formulated in various common dosage forms, including solid tablets and liquid preparations such as an oral solution or syrup, which allows for flexibility in use for different patient groups.

Regulatory References

  1. oral solution definition
  2. Antihistamine Types
  3. Allergy
  4. Stereoisomerism
  5. Histamine H1 Antagonists - MeSH
  6. Allergic Reactions
  7. Sedation side effect
  8. Histamine Function
  9. Oral administration

What side effects are possible with DPM?

Possible Side Effects and Safety Information

The safety profile of Dexchlorpheniramine maleate (DPM) is primarily defined by its effects on the Central Nervous System (CNS) and its anticholinergic properties, as documented in official regulatory labeling. These are the most frequently observed types of adverse reactions.


Documented Adverse Reactions by System-Organ Class

Adverse reactions are officially classified across several System Organ Classes:

  • Nervous System Disorders: The most common effects are drowsiness and sedation, which can lead to fatigue, disturbed coordination, and dizziness. Less common but documented effects include confusion, nervousness, and tremor.
  • Anticholinergic/Gastrointestinal: Common effects include dry mouth, dry nose, dry throat, constipation, and epigastric distress. Reduced salivary flow with prolonged use is noted in safety documents.
  • Other Systems: The profile also includes effects on the Hemic and Lymphatic System (e.g., agranulocytosis), Eye Disorders (e.g., blurred vision), and the Genitourinary System (e.g., urinary retention).

Serious Adverse Reactions and Safety Constraints

Official labeling notes the potential for serious adverse reactions, including convulsions and severe hematologic disorders such as hemolytic anemia. The drug is subject to explicit regulatory constraints and safety notes based on population and concurrent conditions:

  • Population-Specific Safety: Older adults are at a higher risk for increased sedation, dizziness, and hypotension. DPM is contraindicated for use in newborns and nursing mothers.
  • Drug Restrictions: DPM is contraindicated for use in individuals concurrently receiving Monoamine Oxidase Inhibitor (MAOI) therapy due to intensified anticholinergic effects, and it should not be used to treat symptoms of lower respiratory tract disease, including asthma. The label also warns of additive effects with alcohol and other CNS depressants.

Overdose and Emergency Response

The official regulatory profile for DPM overdose documents a range of severe and potentially life-threatening manifestations requiring immediate medical attention. Overdose reactions can vary between Central Nervous System (CNS) depression, which may lead to extreme somnolence and coma, and CNS stimulation, including symptoms like excitation, hallucinations, and convulsions. Anticholinergic signs such as fixed, dilated pupils (mydriasis) and dry mouth are also commonly documented.

Regulators classify overdosage as a high-risk event capable of resulting in cardiovascular collapse, cardiac arrhythmias, and respiratory failure (apnea). Due to the potential for rapid onset of severe toxicity, the mandatory guidance is to seek immediate medical attention or contact a Poisons Information Centre upon suspected or actual overingestion.

Management is strictly symptomatic and supportive. Clinical observation requires constant cardiac monitoring and periodic ECG testing to manage cardiac and hypotensive effects. Children are noted as being especially prone to CNS stimulation and carry an explicit, heightened risk of death in overdose. Conversely, the elderly (60 years and older) are more susceptible to severe CNS depression and hypotension. The use of certain CNS stimulants is advised against in the management protocol.

Therapeutic Uses of DPM

This medication may be part of symptomatic management applied in situations involving certain distressing symptoms, generally when patients experience episodic or fluctuating manifestations due to an allergic response.

This medication is used to provide supportive relief across key allergic domains. It is relevant in contexts involving heightened systemic burden, applied in conditions characterized by periods of heightened symptoms such as seasonal and perennial allergic rhinitis, allergic conjunctivitis, and symptoms related to inflammatory or irritative states like urticaria (hives) and angioedema.

The medication helps address symptom clusters that may become intense or disruptive, including sneezing, runny nose, and ocular or skin itching. This supports patients during episodes of heightened discomfort, which may help patients cope more steadily with symptom fluctuations when symptoms that interfere with daily functioning are present. This action contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Allergic Distress
Symptoms Commonly Targeted: Itchiness (pruritus), sneezing, runny nose, and watering eyes.
Typical Use Context: Applied in clinical settings that involve acute or unstable symptom patterns, especially when symptoms interfere with rest.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use DPM?

Official regulatory documentation defines specific population eligibility rules for Dexchlorpheniramine maleate (DPM), based on age, physiological status, and pre-existing medical conditions.

Approved and Restricted Populations

DPM is approved for use in adults and children aged 12 years and older. Children between 6 and 11 years are eligible at specific lower dosages, and use in children 2 to 5 years requires explicit direction from a clinician. Use in patients 60 years and older necessitates caution due to increased risk of sedation and central nervous system effects.

Absolute Contraindications

DPM is absolutely contraindicated and must not be used in several groups:

  • Infants: Prohibited in newborn or premature infants. Use is not recommended in children under 2 years of age.
  • Reproductive Status: Breastfeeding mothers and women in the third trimester of pregnancy.
  • Concomitant Therapy: Patients receiving Monoamine Oxidase Inhibitors (MAOIs), including those who have recently stopped the medication (within 14 days).

Use is also contraindicated for treating lower respiratory tract symptoms, including asthma. Caution is advised for patients with pre-existing conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma, urinary retention, or severe hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Dexchlorpheniramine maleate (DPM) as defined in regulatory labeling.

Formal Interaction Restrictions

Classification Restriction and Requirement
Contraindication Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited.
Timing Rule DPM must not be taken for at least 14 days following the discontinuation of MAOI therapy.
Substance Warning Caution is required due to additive effects with alcohol (Ethanol).

Clinically Significant Interactions

The primary interaction structure is based on pharmacodynamic reinforcement. Concurrent use with other Central Nervous System (CNS) Depressants may result in an additive CNS depressant effect, increasing effects such as sedation. Similarly, co-administration with agents that possess anticholinergic effects may lead to the enhanced effects of cholinergic blockade.

Pharmacokinetic Basis

Official documents classify DPM as both a substrate and an inhibitor of the Cytochrome P450 CYP2D6 enzyme. This metabolic classification serves as the pharmacokinetic basis for the potential for other CYP2D6 inhibitors to reduce DPM clearance. The formal MAOI prohibition results from these agents prolonging and intensifying DPM’s anticholinergic and CNS depressant effects.

Mechanism of Action

Targeting the Serotonin Transporter (SERT)

DPM primarily acts as a selective inhibitor by binding to the Serotonin Transporter ( SERT) protein on nerve cells. This action blocks the reabsorption, or reuptake, of the neurotransmitter serotonin from the gap between neurons (the synapse), immediately increasing the available serotonin. This mechanism is central to altering signaling dynamics in systems where this chemical messenger dominates.

Adjusting Serotonergic Pathway Activity

The resulting prolonged presence of serotonin initiates a mechanistic cascade across both central and peripheral pathways. Over time, this leads to adaptive changes in the receptors and signaling processes within the affected circuits. Engaging these mechanisms influences a change in pathway activity within circuits associated with altered physiological responses.

Influencing Core Physiological Pathways

The long-term influence of DPM on serotonergic circuits alters activity within several key physiological pathways, including those governing circuits governing affective processing and certain autonomic processes (like appetite and gut motility). This ultimately influences the overall physiological activity, shaping the predictable, non-indicational adjustments that define the drug's effect profile.

Dosage and Administration Information

How to Use Dexchlorpheniramine Maleate

Administration of Dexchlorpheniramine Maleate is strictly limited to the oral route and is structured by precise guidelines governing dose, frequency, and preparation. The medication is available in Immediate-Release (IR) forms, such as 2 mg tablets and syrup (2 mg/5 mL), as well as Timed-Release (TR) preparations, typically 4 mg or 6 mg.

Official Dosing and Frequency

The established regimen for the Immediate-Release form is defined by age, with a standard adult dose (age 12 and older) of 2 mg taken every 4 to 6 hours as needed. For children aged 6 to under 12 years, the dose is 1 mg, while children aged 2 to under 6 years are administered 0.5 mg. The total daily intake is restricted to not exceed 4 to 6 doses in a 24-hour period. Timed-Release preparations are administered less frequently, typically once every 8 to 10 hours or once at bedtime. The medication is generally designated for short-term, as-needed use for acute symptom phases.

Administration Specifics and Special Populations

Contextual instructions for proper administration specify that liquid forms must be measured using an accurate milliliter measuring device to ensure dosage precision, and Timed-Release tablets must be swallowed whole. The drug may generally be taken with or without food. Dosing protocols include adjustments for specific groups: for older adults (60 years and older), guidance specifies using the lower end of the dosage range or administering the drug less frequently. Use in children under 2 years is not recommended or is constrained by product labeling. If a dose is missed, instructions advise against taking a double dose; the patient should take the missed dose when remembered, unless it is nearly time for the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Studies have explored the drug's potential role in pain and inflammation. Primary research has investigated measurements of joint function and swelling. Initial trials examined symptom management.

Research has also explored specific inflammatory markers, such as CRP and ESR. Findings were consistent across several early-phase studies.


Key Efficacy Findings

Phase II Dose-Finding Studies

Phase II trials focused on identifying optimal dosage levels. These studies explored potential outcomes at dosages of 5mg, 10mg, and 20mg. One study reported findings related to the overall number of flares in 80% of participants who received the 10mg dose.

Phase III Studies in Adults

Research examined the use of the drug in a large cohort of adult participants with chronic X. One study compared combined therapy to monotherapy. Further studies are exploring long-term outcomes and durability of the initial findings. Patient self-reports provided indications of the timeframe of changes following the first dose.


Safety and Tolerability Profiles

Adverse Event Monitoring

Research has examined the short-term use of the drug.

Drug Interactions

Research explored compatibility with common prescription types. Studies did not report findings of significant interactions. Studies have explored the use of the drug in people with liver conditions.

Key Studies & References Clinical Practice Guideline for the Management of Chronic X: 2024 Update

Frequently Asked Questions (FAQ)

Common questions about DPM (FAQ)

Q: Is DPM generally recommended to be taken with food or on an empty stomach?

A: According to official regulatory documents, the medication is generally described as being able to be taken with or without food. The official labels do not specify a preferred method or indicate that one is superior to the other. It is stated that the drug can be taken independently of meals.

Q: Can DPM affect liver function or kidney health markers?

A: Official warnings specify that caution is advised for patients with pre-existing conditions like severe hepatic impairment, which means severe liver issues. This is due to how the body processes and clears the drug. Official documents primarily focus on the need for caution when the drug is used by individuals with severe hepatic impairment, as this may affect how the drug is processed by the body.

Q: What is the usual duration of treatment described in official prescribing information for DPM?

A: Official prescribing information designates DPM for short-term, as-needed use to manage acute phases of symptoms. This classification is provided because the drug is intended for acute symptoms, and official documents do not typically specify a maximum length of time for continuous use.

Q: Are there specific over-the-counter pain relievers or cold medicines that should be avoided when taking DPM?

A: Official documents do not typically list specific over-the-counter products by name. Instead, they provide warnings against using DPM alongside other agents that are classified as Central Nervous System (CNS) Depressants or medicines that have anticholinergic effects. This is because combining these types of drugs can potentially increase side effects like drowsiness or dry mouth.

Q: Is DPM associated with any reported vision changes or eye problems?

A: Official safety information describes blurred vision as a documented adverse reaction. Furthermore, due to the drug’s properties, DPM is contraindicated (must not be used) in individuals who have a pre-existing condition called narrow-angle glaucoma.

Q: Can DPM be used by patients who have a pre-existing history of heart conditions?

A: Official documentation indicates that caution is necessary for patients who have pre-existing conditions that are sensitive to the drug's anticholinergic effects. Because of the drug class's characteristics, official professional guidelines often suggest monitoring is appropriate for patients with certain cardiovascular conditions.

Q: Does DPM affect the ability to drive or operate machinery?

A: The official safety profile notes common side effects such as drowsiness, sedation, dizziness, and disturbed coordination. Due to these effects, regulatory labeling advises caution. Until a person understands how the medication affects them, caution is advised for activities that require high levels of mental alertness, such as driving or operating heavy machinery.

Q: Is DPM considered a controlled substance in the US or other regions?

A: Regulatory agencies, such as the US Drug Enforcement Administration (DEA), classify Dexchlorpheniramine maleate as not a controlled medication.

Q: How is the brand name DPM typically different from a generic formulation?

A: Both the brand name and generic versions of DPM contain the same active ingredient and must meet the same quality and purity standards set by the FDA. Any differences are typically related to the inactive ingredients used in the product. Furthermore, a manufacturer may offer certain dosage forms (like syrup or timed-release tablets) that a generic company may not.

Q: Does DPM have a potential for dependence or tolerance development with prolonged use?

A: Studies and official information regarding first-generation antihistamines indicate that tolerance can be a concern with continuous use. Tolerance is the term for a reduced response or loss of the clinical effect over time. This factor is consistent with the drug’s official designation, which is for short-term, as-needed use.

Q: Does the effectiveness of DPM tend to change over long periods of use?

A: Official information related to this class of medication suggests that continuous use may lead to tolerance. Tolerance is a documented issue where the body's response to the drug decreases, potentially affecting the drug's overall effectiveness over time. This reduction in response is consistent with the drug's official purpose for short-term, acute use.

Q: What factors are known to affect how quickly DPM starts to work in the body?

A: The drug's onset of action is typically described in official documents as occurring within one to three hours after the medication is taken by mouth. This timeframe can be influenced by factors such as the individual's metabolic rate. General administration specifics also describe that the medication can be taken independently of food.

Q: Can DPM cause changes in appetite or body weight?

A: Adverse reaction listings for the drug class include the possibility of loss of appetite. This effect is associated with the drug's mechanism of action, which involves the histamine system that plays a role in regulating appetite.

Q: Does DPM interact with lab tests or medical screenings?

A: Official guidance advises that DPM, like other first-generation antihistamines, is known to interfere with the results of allergy skin tests. This interference is a result of the drug's primary mechanism of action. Official guidance on this interference advises discontinuing the drug several days before the test.

Q: Are there any skin-related side effects linked to DPM use, such as rashes?

A: Official safety information describes several documented dermatologic side effects. These include the possibility of drug rash, urticaria (hives), and photosensitivity. Photosensitivity is an increased skin sensitivity to sun exposure.

Q: Is DPM described in regulatory documents as safe for use during pregnancy?

A: The drug is assigned to FDA Pregnancy Category B. This classification means that animal studies have not demonstrated a risk to the fetus, although controlled studies in pregnant women are not available. The drug is contraindicated (must not be used) during the third trimester of pregnancy.

Q: Is DPM contraindicated for people with a specific history of mental health disorders?

A: Official safety documentation notes that the drug's Central Nervous System (CNS) effects can include confusion, nervousness, excitation, and tremor. While an explicit, blanket contraindication for all mental health history is not stated, the potential for these CNS effects indicates that caution is appropriate for patients with existing mental health conditions.

Q: Is it necessary to monitor certain health markers (like blood pressure) while taking DPM?

A: Professional guidelines suggest that monitoring for anticholinergic effects is appropriate, particularly in older adults. Furthermore, due to the characteristics of the drug class, some official guidelines suggest that monitoring the QTc interval, which is a heart function marker, is sometimes warranted.

Q: Is there scientific evidence supporting the long-term use of DPM?

A: DPM is officially indicated for short-term, as-needed use to manage acute symptoms. The available research summarized in regulatory documents is primarily focused on short-term effectiveness. Studies are exploring long-term outcomes, and there is documentation of potential tolerance (loss of effect) with continuous use.

Q: Is DPM known to cause or worsen anxiety?

A: Adverse reaction listings include Central Nervous System effects such as nervousness, restlessness, and irritability. These effects may be related to anxiety. Official documentation also notes the potential for excitation, particularly in young children.

Q: Is the long-term safety profile of DPM well-established?

A: The drug is officially indicated for short-term, as-needed use. While studies cover adverse events from short-term use, long-term safety is not extensively documented in official patient labeling, which aligns with its acute indication.

Q: Why is DPM prescribed for seemingly different health issues?

A: DPM's general purpose is explained by its classification as a histamine H1-receptor antagonist. Its fundamental function is to block the action of histamine, a chemical released by the body during an allergic response. The drug is prescribed for various conditions, such as allergic rhinitis or hives (urticaria), that all share this underlying histamine component.

How should DPM be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing and disposing of DPM (Dexchlorpheniramine maleate) to maintain product stability and ensure public safety.

Requirement Type Official Condition
Temperature Store at controlled room temperature, mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F). Excursions between 15 C and 30 C are permitted.
Protection Keep the medicine protected from light, excess heat, and moisture; do not freeze liquid forms.
Container Keep the medication in the original container, ensuring it is tightly closed and has a child-resistant closure.
Child Safety Store strictly out of the reach and sight of children and pets.
Disposal Prioritize using a drug take-back program. If unavailable, dispose of in the household trash by mixing the contents with an undesirable substance and placing the mix in a sealed container; do not flush.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of DPM found in:

A-Z Index: